TXNRD1 and cancer: Recent studies have reported ROS induction can be increased in cancer cells by targeting thioredoxin reductase 1 (TrxR1) and by depleting the cellular glutathione (GSH) level (in Figure 4) (Chen et al., 2019; Zhao et al., 2023).